默沙东与第一三共联合研发的ADC启动前列腺癌三期临床

药事纵横
20 Jun

据默沙东6月18日消息,该公司与第一三共联合研发的ADC药物ifinatamab deruxtecan(I-DXd)已启动三期临床试验(IDeate-Prostate 01),并且首例患者已经完成给药。IDeate-Prostate 01试验旨在评估ifinatamab deruxtecan(I-DXd)对比多西他赛在经雄激素受体通路抑制剂治疗后出现疾病进展的转移性去势抵抗性前列腺癌(mCRPC)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10